~~<i id='EEBE12B492'><strike id='EEBE12B492'><tt id='EEBE12B492'><pre id='EEBE12B492'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：focus 2025-09-30 00:10:08 - browse：3

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Virtual care provider acquires bankrupt Pear's prescription apps

knowledge

hotspot

focus

explore

entertainment

focus

AdobeAlmostassoonasChatGPTwasreleasedtothepublic,doctorsbeganfocusingonhowtheycouldharnessartificial

WSS

What STAT readers think about the FDA and patient advocacy

Virtual care provider acquires bankrupt Pear's prescription apps

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

In Spain, a hospital brews its own CAR

Grail spinoff by Illumina should end disastrous merger attempt

Merck, Daiichi strike cancer drug pact worth up to $22 billion

knowledge

focus

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

CRISPR gene editing developments we’re watching in 2024

BioMarin wins approval for gene therapy to treat hemophilia A

Roche acquires Telavant from Roivant, adding experimental IBD treatment

23andMe had bad news about my health. I wish a person had delivered it

Roche drug slashes death risk in early

Sports medicine is finally prioritizing gender equality

Roivant's CEO is a star, but biotech's black hole persists

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

hotspot

Roche drug slashes death risk in early

Violet CEO on training clinicians to promote more inclusive care

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Violet CEO on training clinicians to promote more inclusive care

focus

explore

entertainment

focus